Amgen registers Phase 3 MARITIME-PEN trial testing home autoinjector for maridebart cafraglutide

Amgen's single update of the week concerns a newly listed trial for its investigational obesity treatment.

• "A Phase 3 Multicenter, Open-label, Single-arm Trial Evaluating Home Self-Administration of Subcutaneous Maridebart Cafraglutide Via Autoinjector in Adult Participants Living With Obesity or Overweight Without Type 2 Diabetes Mellitus" is recruiting under the acronym MARITIME-PEN. The study's main objective is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.¹ It plans to enroll 230 participants in a single-arm design in which participants receive 8 total doses of subcutaneous injections of maridebart cafraglutide.¹ Primary completion is estimated for 2027-06-16.